Back to top
more

Range Cancer Therapeutics ETF: (CNCR)

(Delayed Data from NASDAQ) As of May 28, 2024 03:12 PM ET

$14.34 USD

14.335
2,146

-0.28 (-1.88%)

Volume: 2,146

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

ETF Quote Details

Previous Close 14.61
Open 14.75
Bid 13.69
Ask 17.98
Day Low-High 14.34-14.75
52wk Low-High 9.22-17.96
Volume 2,146
NAV (month end) 14.80
Premium (+)/Discount (-) (month end)-0.19

Zacks Premium Research for CNCR

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

Buy 2
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

High
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $0.00 (0.00%)
Issuer RANGE

Benchmark for CNCR

RANGE CANCER THERAPEUTICS INDEX

The Range Cancer Therapeutics Index tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts with a market capitalization of more than $250 million.

Fund Summary for CNCR

RANGE CANCER THERAPEUTICS ETF

The Range Cancer Therapeutics ETF seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index.